Content deleted Content added
The Nth User (talk | contribs) →References: Added one category |
VastV0idInSpace0 (talk | contribs) →References: Fixed spacing between stub template and category templates. Tag: 2017 wikitext editor |
||
| (6 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| Line 19: | Line 20: | ||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 406205-74-1 |
| CAS_number = 406205-74-1 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 5FO5Z101GU |
|||
| PubChem = 10479060 |
| PubChem = 10479060 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| Line 32: | Line 35: | ||
}} |
}} |
||
'''BAY 59-3074''' is a drug which is a [[cannabinoid receptor]] [[partial agonist]] developed by [[Bayer|Bayer AG]]. It has [[analgesic]] effects and is used in scientific research. It is orally active in animals, and has modest affinity for both [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptors, with [[Dissociation constant|K<sub>i</sub>]] values of 48.3nM at CB<sub>1</sub> and 45.5nM at CB<sub>2</sub>.<ref>{{cite journal | |
'''BAY 59-3074''' is a drug which is a [[cannabinoid receptor]] [[partial agonist]] developed by [[Bayer|Bayer AG]]. It has [[analgesic]] effects and is used in scientific research. It is orally active in animals, and has modest affinity for both [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptors, with [[Dissociation constant|K<sub>i</sub>]] values of 48.3nM at CB<sub>1</sub> and 45.5nM at CB<sub>2</sub>.<ref>{{cite journal | vauthors = De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F | title = 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 2 | pages = 620–32 | date = August 2004 | pmid = 15140913 | doi = 10.1124/jpet.103.062836 | s2cid = 17980901 }}</ref><ref>{{cite journal | vauthors = De Vry J, Jentzsch KR | title = Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat | journal = European Journal of Pharmacology | volume = 505 | issue = 1–3 | pages = 127–33 | date = November 2004 | pmid = 15556145 | doi = 10.1016/j.ejphar.2004.10.012 }}</ref> |
||
==References== |
== References == |
||
{{reflist}} |
|||
<references/> |
|||
{{cannabinoids}} |
{{cannabinoids}} |
||
| Line 41: | Line 44: | ||
[[Category:Cannabinoids]] |
[[Category:Cannabinoids]] |
||
[[Category:Trifluoromethyl compounds]] |
[[Category:Trifluoromethyl compounds]] |
||
[[Category: |
[[Category:2-Hydroxybenzonitrile ethers]] |
||
[[Category:Phenyl sulfonate ethers]] |
[[Category:Phenyl sulfonate ethers]] |
||
[[Category:Diphenyl ethers]] |
[[Category:Diphenyl ethers]] |
||
[[Category:Resorcinol ethers]] |
[[Category:Resorcinol ethers]] |
||
{{cannabinoid-stub}} |
{{cannabinoid-stub}} |
||
Latest revision as of 21:47, 8 February 2024
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H13F6NO4S |
| Molar mass | 453.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
BAY 59-3074 is a drug which is a cannabinoid receptor partial agonist developed by Bayer AG. It has analgesic effects and is used in scientific research. It is orally active in animals, and has modest affinity for both CB1 and CB2 receptors, with Ki values of 48.3nM at CB1 and 45.5nM at CB2.[1][2]
References[edit]
- ^ De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F (August 2004). "3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 620–32. doi:10.1124/jpet.103.062836. PMID 15140913. S2CID 17980901.
- ^ De Vry J, Jentzsch KR (November 2004). "Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat". European Journal of Pharmacology. 505 (1–3): 127–33. doi:10.1016/j.ejphar.2004.10.012. PMID 15556145.